drugset / Trial / NCT06052254

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

NCT06052254

Phase 2 Recruiting 150 enrolled Teikoku Pharma USA, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.

Timeline

Start
2025-09-16
Primary completion
2027-05
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified Other

Indications

No indication recorded.